Atrial Fibrillation: Rivaroxaban Monotherapy Study

We are exploring the safety of rivaroxaban in patients with atrial fibrillation who have had a heart procedure. This study aims to see if this treatment is a viable option for these patients.

>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOralCardiologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Xarelto
Xarelto is a medicine that helps prevent and treat blood clots and reduce stroke risk in people with an irregular heartbeat.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Rivaroxaban
Rivaroxaban is a substance that helps prevent and treat blood clots by blocking a key clotting protein, lowering the risk of stroke and embolism.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Aban
Agublon
Assubex

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Amsterdam UMC
Cardiology
Amstelveen, Netherlands
Sponsor: Amsterdam UMC
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.